TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04038385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Behavioral Intervention
Description: Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
Study: NCT00633893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, twice daily, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, twice daily, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, twice daily, 12 months
Study: NCT02891772

Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of corrected flow time(FTc) in carotid artery
Description: Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
Study: NCT02831283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: 11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-PBR28
Description: 11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: 18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetaben
Description: 18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
Study: NCT01037751

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
Study: NCT05469100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT00092222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
Study: NCT05469100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT00092222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim (G-CSF)
Description: Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Maximum daily dose of 40 mg given as a single agent on 21 day cycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Only
Description: Observation of symptoms
Study: NCT04107766

Intervention type: DEVICE
Intervention: Microwave Ablation
Description: Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
Study: NCT00871676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: 16 weekly followed by 8 monthly group behavioral weight loss sessions.
Study: NCT02779855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m\^2.
Study: NCT00871676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus gum
Description: 16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
Study: NCT01488188

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administration of 1 dose (0.2 ml) by nasal route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administration of 1 dose (0.2 ml) by sublingual route
Study: NCT00959699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PegIFN-2b
Description: PegIFN-2b (1.5 μg/kg/week subcutaneously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN-2b
Description: PegIFN-2b (1.5 μg/kg/week subcutaneously)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RBV
Description: Ribavirin (600-1400 mg/day, orally, divided into two daily doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
Study: NCT05070741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
Study: NCT00959699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Boceprevir
Description: Placebo to boceprevir (orally, three times per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Boceprevir (800 mg, orally, three times per day)
Study: NCT04159701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3454738
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02622048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Positive Parenting Programme
Description: 10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
Study: NCT04313673

Intervention type: DIAGNOSTIC_TEST
Intervention: second trimester ultrasonography
Description: Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
Study: NCT01553591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets twice daily
Study: NCT00260091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infertility
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infertility
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
Study: NCT03151538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Mixed With Play
Description: To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled
Description: First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
Study: NCT02120469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT04500223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Cranioflexion exercise plus cardiopulmonary exercise
Description: Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stretch exercise plus cardiopulmonary rehabilitation
Description: control:Cervical stretch exercise plus cardiopulmonary rehabilitation
Study: NCT02971007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: lipid-crystal nano-particle formulation amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: lipid-crystal nano-particle formulation amphotericin B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study: NCT01704976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SR-WBV
Description: Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SR-WBV
Description: Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
Study: NCT02620046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC 108 mg injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC 108 mg injection
Study: NCT01554189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8325
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match MK-8325 capsules, orally, once per day for 5 days
Study: NCT01547962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous Free Gingival Graft (FGG)
Description: Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
Study: NCT02741310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan
Description: Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by intravenous infusion
Study: NCT02977507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera 2.0
Description: Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Hydroquinone Topical Cream
Description: 4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Facial Cleanser
Description: SkinMedica facial cleanser applied to the face as directed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Facial Cleanser
Description: SkinMedica facial cleanser applied to the face as directed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Rejuvenative Moisturizer
Description: SkinMedica rejuvenative moisturizer applied to the face as directed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Rejuvenative Moisturizer
Description: SkinMedica rejuvenative moisturizer applied to the face as directed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Description: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Description: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
Study: NCT02438761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Study: NCT00633360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone and ethinyl estradiol
Description: Once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily by mouth
Study: NCT02219737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03030014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational programm
Description: Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no educational program
Description: without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.